revealed that GPX3 hypermethylation in head and neck cancer (HNC) correlated with chemoresistance (cisplatin‐based chemotherapy), and could serve as a potential marker predicting the prognosis of HNC patients 15. This evidence concerns the gene GPX3 and head and neck cancer.